Roche's Avastin nabs cervical cancer use in EU; Havas lays off staffers in wake of Merck OTC loss;

> Roche's ($RHHBY) Avastin won European approval as a treatment for women with advanced cervical cancer. Release

> Havas laid off more than a dozen workers after Bayer bought Merck & Co.'s ($MRK) consumer drug business and pulled Merck's OTC brand accounts from the agency. Report

> Public Citizen is asking the FDA to call a halt to diabetes drug ads that mention weight loss, despite current language emphasizing that the meds aren't diet drugs. Report

> Gilead Sciences ($GILD) filed its latest HIV therapy for approval in the U.S.; it's a combo drug comprising Emtriva (emtricitabine), and a low-dose formula of tenofovir, the active ingredient in its existing drug Viread. Report

> Using cost-effectiveness as a way to build a drug formulary cut pharmacy costs by 3% in a study of one Blue Cross program. Report

And Finally... Talk about direct-to-patient delivery: Amazon ($AMZN) Prime Air could eventually allow scripts dispensing via drone. Report

Suggested Articles

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

Their merger isn't official yet, but a new logo is ready to go: Mylan and Pfizer's Upjohn unit unveiled new branding for their Viatris combo Thursday.

AbbVie's Allergan received a positive early ruling in its long-running trade secrets dispute with Evolus over a competitor to blockbuster Botox.